ODI Pharma moves the AGM and postpones the publication of Annual Report 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby hereby announces that the Company, due to administrative reasons, chooses to move the Annual General Meeting to a later date and also postpone the publication of the Annual Report for the financial year 2023/2024.

The Annual General Meeting was originally scheduled to be held on December 13, 2024. Due to administrative reasons, ODI Pharma has chosen to postpone the AGM. The Company will issue a new notice for the AGM no later than four weeks before the new date. This also means that the publication of the annual report for the fiscal year 2023/2024 will be postponed, it will be available three weeks before the AGM.

The meeting will be held in accordance with current legislation and the Company’s articles of association.

For more information on ODI Pharma, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: [email protected]  

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.